These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 21288184)
21. Botulinum toxin for the management of bladder dysfunction. Schurch B Drugs; 2006; 66(10):1301-18. PubMed ID: 16903766 [TBL] [Abstract][Full Text] [Related]
22. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Kalsi V; Popat RB; Apostolidis A; Kavia R; Odeyemi IA; Dakin HA; Warner J; Elneil S; Fowler CJ; Dasgupta P Eur Urol; 2006 Mar; 49(3):519-27. PubMed ID: 16413656 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658 [TBL] [Abstract][Full Text] [Related]
26. [Botulinum toxin injection for refractory non-neurogenic overactive bladder. Systematic review]. Henriet B; Roumeguère T Rev Med Brux; 2015; 36(1):29-37. PubMed ID: 25856969 [TBL] [Abstract][Full Text] [Related]
27. Intradetrusor injection of botulinum toxin for the management of refractory overactive bladder syndrome: an update. Al-Shaiji TF Surg Innov; 2013 Aug; 20(4):351-5. PubMed ID: 22964263 [TBL] [Abstract][Full Text] [Related]
28. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin? Tubaro A; Puccini F; De Nunzio C Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873 [TBL] [Abstract][Full Text] [Related]
29. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder. Ellsworth P; Travis M Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617 [TBL] [Abstract][Full Text] [Related]
30. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020 [TBL] [Abstract][Full Text] [Related]
31. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment. Harris MA; Harding C; Fulford S; Whiteway J BJU Int; 2011 Apr; 107(7):1165; author reply 1165. PubMed ID: 21438980 [No Abstract] [Full Text] [Related]
32. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Fowler CJ; Auerbach S; Ginsberg D; Hale D; Radziszewski P; Rechberger T; Patel VD; Zhou J; Thompson C; Kowalski JW Eur Urol; 2012 Jul; 62(1):148-57. PubMed ID: 22464310 [TBL] [Abstract][Full Text] [Related]
33. Experience with injections of botulinum toxin type A into the detrusor muscle. Miyagawa I; Watanabe T; Isoyama T; Honda M; Kobayasi N; Hikita K; Saito M; Hirakawa S Aktuelle Urol; 2010 Jan; 41 Suppl 1():S24-6. PubMed ID: 20094947 [TBL] [Abstract][Full Text] [Related]
34. Should we stop using botulinum neurotoxin type a in patients with neurogenic detrusor overactivity after development of secondary resistance? Pistolesi D; Giannarini G; Stampacchia G; Selli C Eur Urol; 2011 Oct; 60(4):872-3. PubMed ID: 21802198 [No Abstract] [Full Text] [Related]
35. Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis. Cui Y; Wang L; Liu L; Zeng F; Niu J; Qi L; Chen H Urol Int; 2013; 91(4):429-38. PubMed ID: 23970316 [TBL] [Abstract][Full Text] [Related]
36. Effects of botulinum toxin type a in the bladder wall of children with neurogenic bladder dysfunction: a comparison of histological features before and after injections. Pascali MP; Mosiello G; Boldrini R; Salsano ML; Castelli E; De Gennaro M J Urol; 2011 Jun; 185(6 Suppl):2552-7. PubMed ID: 21527192 [TBL] [Abstract][Full Text] [Related]
37. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). Mohee A; Khan A; Harris N; Eardley I BJU Int; 2013 Jan; 111(1):106-13. PubMed ID: 22672569 [TBL] [Abstract][Full Text] [Related]
38. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease. Kulaksizoglu H; Parman Y Parkinsonism Relat Disord; 2010 Sep; 16(8):531-4. PubMed ID: 20637678 [TBL] [Abstract][Full Text] [Related]